The FDA enforcement report dated 14 October lists Class II recalls from Carolina Infusion, a US compounding pharmacy, covering compounded semaglutide 3 mg/mL syringes and related semaglutide and tirzepatide combinations with cyanocobalamin. The stated reason is lack of assurance of sterility, linked to the use of bacteriostatic water and to processing equipment. The recall is listed as ongoing.
A Class II recall means use may cause temporary or medically reversible harm, or that serious harm is remote. It is a manufacturing and quality action, not a new safety signal for the licensed medicines.
The products were sold in the United States. The wider lesson travels: compounded and unlicensed incretins, often sold online or mixed with vitamins, carry quality risks that the licensed pens do not.
- Ask patients where their semaglutide or tirzepatide comes from, especially if it arrives in syringes rather than a pen.
- Vitamin B12 combinations and syringe packs are features of compounded products, not licensed ones.
- Check injection sites and ask about fever in anyone using compounded injectables.
- This recall concerns one US pharmacy's products; it does not affect licensed pens.
Why it matters
Demand has pushed patients toward compounded and online incretins, and their quality is not guaranteed.
Read the rest in the app
You have read your two free briefings this month. The app carries all 27 specialties, every morning, free — and this finding is waiting in it.
Scan to keep reading on your phone. No account needed to start.
Tomorrow morning, before your first patient
One edition a day for diabetes & endocrinology, written by the desk, every claim tied to its paper. Six minutes.
Get the app — free